Zhou Zhidong, MD, Ph.DAssociate Clinician Scientist, Translational Therapeutics LaboratoryAdjunct Assistant Professor at Duke-NUS Medical School
Translational Therapeutics LaboratoryDuke-NUS Graduate Medical School, NBD, Level 68 College Road, Singapore 169857Tel: (65) 6601 3742 (Office) Fex: (65) 6256 9178Email: email@example.com
Xie Shao Ping, MSc (Research Fellow)Sushmitha Sathiyamoorthy, MSc (Research Fellow)Saw Wuan Ting, MSc (Research Fellow)Heidi Pek Hup Chua, BSc Hons (Senior Research Assistant)
NMRC NIG and NMRC TA awards SingHealth Foundation Grant
Our laboratory’s interests lie in identification and verification of novel key molecular targets, signaling pathways or neuro-protective agents relevant to pathogenesis and therapy of debilitating human neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson disease (PD) and multiple sclerosis.
To achieve it, cutting-edged high throughput screening works are being performed in the lab. First, the in vitro high throughput proteomics screening plus immuno-precipitation protocols as well as cellular and molecular techniques are utilized to search and identify new key molecular targets or novel signaling pathways relevant to pathogenesis and therapy in human neurodegenerative diseases. Second, in vitro high throughput chemical library screening is being performed to identify new neuro-protective agents to modulate identified new molecular targets or signaling pathways for future clinical drugs developments. Findings from in vitro identification of new targets or new neuron protective agents will be further strengthened by our in vivo verification studies in our environmental or genetic Drosophila or mice disease models. Third, direct in vivo high throughput screening using our newly established toxic in vivo Drosophila models is used to search for new dopamine neuron degeneration relevant genes or new potential anti-PD drugs for PD pathogenesis and therapy.
These researches are conducted in close collaboration with Professor Tan Eng King, Research Director, NNI and Senior Consultant, Department of Neurology, NNI (Singapore General Hospital. campus) to emphasize potential clinical implications and applications of our findings. Our works will not only advance our understanding of the pathogenesis of human degenerative disorders, but also can benefit patients via contribution of new therapeutic agents or strategies against human neuron degenerative diseases in the future.
Subcribe to our mailing list to get the updates to your email inbox...
Best viewed on IE 11, Firefox 27, Chrome 22, and Safari 7 and above.